ATE435024T1 - Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie - Google Patents

Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie

Info

Publication number
ATE435024T1
ATE435024T1 AT04730882T AT04730882T ATE435024T1 AT E435024 T1 ATE435024 T1 AT E435024T1 AT 04730882 T AT04730882 T AT 04730882T AT 04730882 T AT04730882 T AT 04730882T AT E435024 T1 ATE435024 T1 AT E435024T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
treatment
amyloid brain
brain angiopathy
Prior art date
Application number
AT04730882T
Other languages
German (de)
English (en)
Inventor
Barrio Manuel Sarasa
Original Assignee
Araclon Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech Sl filed Critical Araclon Biotech Sl
Application granted granted Critical
Publication of ATE435024T1 publication Critical patent/ATE435024T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04730882T 2003-05-08 2004-05-03 Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie ATE435024T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer

Publications (1)

Publication Number Publication Date
ATE435024T1 true ATE435024T1 (de) 2009-07-15

Family

ID=32982086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04730882T ATE435024T1 (de) 2003-05-08 2004-05-03 Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie

Country Status (19)

Country Link
US (6) US20090162362A1 (enExample)
EP (5) EP2082747A3 (enExample)
JP (5) JP2006525288A (enExample)
CN (2) CN101264326A (enExample)
AT (1) ATE435024T1 (enExample)
AU (2) AU2004237373A1 (enExample)
BR (1) BRPI0410684A (enExample)
CA (1) CA2524571C (enExample)
CY (1) CY1109454T1 (enExample)
DE (1) DE602004021797D1 (enExample)
DK (3) DK2075007T3 (enExample)
ES (6) ES2246177B1 (enExample)
IL (8) IL171651A (enExample)
MX (1) MXPA05010914A (enExample)
PL (3) PL2075007T3 (enExample)
PT (3) PT2075007E (enExample)
RU (2) RU2385161C2 (enExample)
SI (1) SI1623719T1 (enExample)
WO (1) WO2004098631A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
RU2498999C2 (ru) * 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2510359B1 (en) 2009-12-11 2015-09-02 Araclón Biotech, S. L. Methods and reagents for improved detection of amyloid beta peptides
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US20130115227A1 (en) * 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
US9221900B2 (en) * 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
WO1990012870A1 (en) * 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP1105163A4 (en) * 1998-08-20 2003-05-02 Univ California METHOD FOR MARKING AMYLOID PLAQUES AND NEUROFIBRILLIC GIFTS
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
AU2003279216A1 (en) * 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Also Published As

Publication number Publication date
IL207881A0 (en) 2011-07-31
MXPA05010914A (es) 2006-03-21
AU2011200170C1 (en) 2012-03-22
ES2246105A1 (es) 2006-02-01
ES2246177B1 (es) 2007-03-01
JP2016065100A (ja) 2016-04-28
EP1623719B1 (en) 2009-07-01
EP2305286A3 (en) 2011-11-09
IL207881A (en) 2013-02-28
IL207879A0 (en) 2011-07-31
SI1623719T1 (sl) 2009-12-31
ES2246105B1 (es) 2007-03-01
BRPI0410684A (pt) 2006-06-20
CN1784240A (zh) 2006-06-07
JP2006525288A (ja) 2006-11-09
CA2524571C (en) 2017-01-10
IL207876A (en) 2013-03-24
ES2246177A1 (es) 2006-02-01
ES2246178A1 (es) 2006-02-01
US20200140488A1 (en) 2020-05-07
CY1109454T1 (el) 2014-08-13
DK2356996T5 (da) 2013-08-26
ES2423590T3 (es) 2013-09-23
JP2012006967A (ja) 2012-01-12
EP2305286A2 (en) 2011-04-06
ES2246178B1 (es) 2007-03-01
EP2075007B9 (en) 2013-09-04
DK2356996T3 (da) 2013-07-22
AU2011200170B2 (en) 2011-09-01
CA2524571A1 (en) 2004-11-18
IL207879A (en) 2013-02-28
IL207876A0 (en) 2011-07-31
EP1623719A1 (en) 2006-02-08
JP2014129389A (ja) 2014-07-10
IL207877A (en) 2013-03-24
US20110262458A1 (en) 2011-10-27
AU2004237373A1 (en) 2004-11-18
IL207877A0 (en) 2011-07-31
JP2018119011A (ja) 2018-08-02
PL1623719T3 (pl) 2010-11-30
IL207880A (en) 2013-02-28
EP2075007A3 (en) 2009-11-11
DK2075007T3 (da) 2013-07-29
PT2075007E (pt) 2013-08-23
EP2075007B1 (en) 2013-05-22
RU2005134351A (ru) 2006-04-27
IL207878A0 (en) 2011-07-31
EP2356996A1 (en) 2011-08-17
US20090162362A1 (en) 2009-06-25
WO2004098631A1 (es) 2004-11-18
US20140044725A1 (en) 2014-02-13
PL2075007T3 (pl) 2013-09-30
ES2329369T3 (es) 2009-11-25
PT2356996E (pt) 2013-08-23
DE602004021797D1 (de) 2009-08-13
EP2075007A2 (en) 2009-07-01
RU2009148539A (ru) 2011-06-27
ES2423281T3 (es) 2013-09-19
CN101264326A (zh) 2008-09-17
US20210214394A1 (en) 2021-07-15
IL207875A (en) 2013-02-28
RU2385161C2 (ru) 2010-03-27
EP2082747A2 (en) 2009-07-29
IL207875A0 (en) 2011-07-31
IL171651A (en) 2011-11-30
DK1623719T3 (da) 2009-11-09
AU2011200170A1 (en) 2011-02-03
RU2526155C2 (ru) 2014-08-20
PL2356996T3 (pl) 2013-09-30
PT1623719E (pt) 2009-10-08
US20170260234A1 (en) 2017-09-14
EP2356996B9 (en) 2013-08-28
EP2356996B1 (en) 2013-06-26
IL207878A (en) 2013-02-28
IL207880A0 (en) 2011-07-31
EP2082747A3 (en) 2010-01-13

Similar Documents

Publication Publication Date Title
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
ATE495755T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
DE60221665D1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ATE344316T1 (de) Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
EP1614428A4 (en) MEDICAMENT FOR PREVENTING OR TREATING ANGIOGENIC EYE DISEASES
DE60234031D1 (de) Mittel zur behandlung allergischer augenerkrankungen
DE60223674D1 (de) Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten
WO2003087835A8 (en) Haptoglobin fragments diagnostic of alzheimers disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1623719

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1623719

Country of ref document: EP